Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Agents inhibiting the phosphoinositide 3–kinase–Akt–mammalian target of rapamycin (PAM) pathway are currently in various stages of clinical development in oncology, ranging from some in early-phase evaluations to others that have already received regulatory approval for treatment in advanced cancers...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Busaidy, Naifa L., Farooki, Azeez, Dowlati, Afshin, Perentesis, John P., Dancey, Janet E., Doyle, Laurence A., Brell, Joanna M., Siu, Lillian L.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2012
Fag:
Special Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410405/
https://ncbi.nlm.nih.gov/pubmed/22778315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.7356
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker